Interested in stem cell developments.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
No
Yes (a bit)
Yes
No
With respect to the insider comments I think that Smart Scan has merely picked up Lanza's pre-established and public sell program.
Good observation rocky, and I would say it is good news that Lanza decided not to sell at this level.
Poll finds widespread US support for embryonic stem cell research
http://www.pharmatimes.com/Article/10-10-21/Poll_finds_widespread_US_support_for_embryonic_stem_cell_research.aspx
Great work on these court matters rocky. Is there any way we find out what the settlement was?
Filing deadlines set in US stem cell appeal
http://blogs.nature.com/news/thegreatbeyond/2010/09/filing_deadlines_set_in_us_ste.html
Hey rumit, funny thing is I did post it on the Yahoo Board but over here they sometimes take off posts or articles that don't specifically refer to ACTC so I often skip posting such here, but I am glad to see you got this one in.
ACTC is not moving away from the RPE program. ACTC is merely reflecting the capacity to do more than one thing at a time (I hate the word multitask so I don't want to even mention it in this post).
I think the hold on the ACTC IND has nothing to do with the ACTC IND or ACTC PR, etc., etc. I own shares in both ACTC and Geron but am considerably more invested in ACTC. Nevertheless, I do think that at this point the FDA has an obligation to Geron. Geron paved the way for hESC study approval from the FDA by putting a tremendous amount and variety of effort, including an unusually high amount of consultation with the FDA, and others, in developing their 21,000-page IND application based on 24 animal studies utilizing billions of hESC cells which, among other important things, helped to determine the safety of hESCs by showing no teratomas. Geron then had a long hold based mostly on excessive caution by Geron and the FDA before being given the current go ahead. At this point the FDA owes Geron the opportunity to at least initiate the history making first hESC treatment under FDA auspices (unless some other serious delay of the Geron study is found to be necessary or finding apppropriate patients proves to take too long). I think approval of the ACTC IND will happen shortly after Geron initiates treatment in their study. And given that, it still does seem likely to me, because of the nature of the different studies, that ACTC will, in fact, have significant results before Geron and will complete their study before Geron completes theirs.
Government Asks District Judge to Dismiss Stem Cell Suit
by Jocelyn Kaiser, Science Insider, 28 September 2010, 12:23 PM
The legal wrangling over stem cell research continues. Yesterday, the same day an appeals court questioned lawyers about the case, the government filed documents in a lower court arguing that the lawsuit brought by two researchers who oppose human embryonic stem cell (hESC) research should be thrown out.
To recap: On 23 August, U.S. District Judge Royce Lamberth issued a preliminary injunction freezing National Institutes of Health (NIH) support for hESC research because it likely violates the Dickey-Wicker law banning federal funds for research that harms embryos. After an appeals court temporarily lifted the freeze, the plaintiffs, two researchers who study adult stem cells, filed a "motion for summary judgment" with Lamberth. This means they argued that the facts aren't in dispute and the judge can rule quickly without a trial on issuing a permanent injunction.
Last night the Department of Justice (DOJ) submitted a 21-page response to the plaintiffs' statement of facts supporting their motion, arguing that many of the facts are incorrect or not relevant to the case. For example, DOJ lawyers dispute the suggestion that hESC and adult stem cell research proposals compete directly for funding, and they say the plaintiffs' statements about the status of adult stem cell research are irrelevant.
Justice lawyers also filed their own 54-page motion for summary judgment asking the court to rule in their favor. It repeats the argument that NIH's interpretation of Dickey-Wicker is valid because Congress and three presidential administrations have supported it. The government also disputes the plaintiff's claim that NIH didn't follow proper administrative procedures when it issued draft guidelines for hESC research because the agency ignored many of the 49,000 comments it received. NIH asked for comments on how to implement President Barack Obama's March 2009 executive order expanding hESC research, not whether to fund hESC research, according to a declaration from Story Landis, chair of NIH's stem cell task force. (As an example, NIH received more than 10,000 nearly identical comments at the urging of two groups opposed to hESC research. NIH deemed these irrelevant, Landis states.)
Even if the court agrees with the plaintiffs' arguments, it should hand the guidelines back to NIH to revise them, not issue a permanent injunction, the government concludes.
The plaintiffs now have until 7 October to respond, then there is another deadline for documents from both sides later in October, although Lamberth could rule before then. For the moment, all eyes are on the appeals court, which could rule soon on whether to extend the current stay lifting the preliminary injunction—essentially, whether hESC research can continue while the case moves through the courts or must again grind to a halt.
And Dante didn't even know about credit default swaps.
US Appeals Court Appears Divided In Stem Cell Case
By Brent Kendall, Of DOW JONES NEWSWIRES, 09-27-10, 12:46ET
WASHINGTON -(Dow Jones)- A federal appeals court appeared divided Monday on whether to temporarily suspend a trial judge's ban on federal funding for embryonic stem-cell research.
During a lengthy oral argument, a three-judge panel of the U.S. Court of Appeals for the District of Columbia Circuit pressed the Obama administration on its argument that the federal government would suffer irreparable harm if the funding ban was enforced.
Judge Thomas Griffith was the most aggressive questioner of the government. He suggested that even if federally funded embryonic research is halted now, researchers could resume their experiments later if the government eventually wins in court.
Judge Brett Kavanaugh also asked skeptical questions of the Justice Department lawyer who was arguing to keep the funding in place. Kavanaugh called the government's position "odd" and "internally inconsistent." However, he also suggested that it may be appropriate to defer to the government's views because the law at issue in the case is ambiguous.
Both Griffith and Kavanaugh are appointees of former president George W. Bush.
Judge Judith Rogers, a Clinton appointee, appeared the most sympathetic to the government's case. She suggested that even a temporary halt to research funding could damage the public's interest in embryonic stem cell research.
Stem cells are the building blocks of the body's tissues and organs. Those derived from embryos can develop into any type of tissue and are considered especially promising for research. Opponents of the research, however, say destroying an embryo to get the cells amounts to taking a human life.
One of President Barack Obama's first acts on science policy after taking office was to take down barriers to stem-cell research set up by President George W. Bush in August 2001.
A trial judge ruled last month that government funding for embryonic stem-cell research was barred by a 1996 law that prohibits the use of federal money for research in which an embryo is destroyed. The judge issued a preliminary injunction halting the funding.
The surprise ruling was a blow to the Obama administration's bid to expand stem-cell research, a contentious area of study that holds promise for research into diseases such as diabetes and heart disease.
On Monday, the appeals court was considering whether to temporarily suspend enforcement of the trial judge's ruling while the legal case is resolved in the courts.
That resolution could take several months or longer.
Justice Department lawyer Beth Brinkmann argued that an immediate stay of the injunction was needed to avoid terminating research projects midstream and wasting taxpayer dollars already invested in the research.
Thomas Hungar, a lawyer for two doctors that oppose the research, said government funding of the research was in clear violation of the law.
Hungar also disputed the argument that the government would be irreparably harmed if the research projects were idled while the case proceeds in the court.
Monday's argument session was scheduled to last 30 minutes, but the judges peppered the lawyers with questions for more than an hour.
The appeals court did not give any indication on when it might rule.
-By Brent Kendall, Dow Jones Newswires; 202-862-9222; brent.kendall@ dowjones.com -0-
Ah, Dorothy, it's just a new wrinkle on the same old hell.
rocky and rumit, you both have done a good job of indicating the evidence from the results and conclusions of their previous work, as well as additional comments on same, that Lanza and SCRMI thought they were much closer to a source of universal red blood cells (RBCs) and platelets with hESCs than with iPSCs. That was my reading of it also and you left me more convinced of it. So I now must suggest there is a good possibility that the nature of this Director's Opportunity Award (in Five Thematic Areas) is not a reflection of a change of direction for Lanza et. al. but is more a reflection of priorities set by NIH and includes some that are contingent on the current intense political climate. NIH may very well have made it clear, in various ways, that they were much more likely to fund work with iPSCs than with hESCs. Lanza and Kim may have responded accordingly. I am sure Lanza, et. al., are, in any case, happy to move ahead on both fronts and certainly there is plenty of synergy between these efforts so that impact of work on the iPSCs is almost certain to also benefit the ongoing work on hESCs (and may even allow, one way or another, for the borrowing of a test-tube or two).
Abstract of 2007 fusion protein study
Recombinant HoxB4 fusion proteins enhance hematopoietic differentiation of human embryonic stem cells.
Stem Cells Dev. 2007 Aug;16(4):547-59.
Lu SJ, Feng Q, Ivanova Y, Luo C, Li T, Li F, Honig GR, Lanza R.
Advanced Cell Technology, Worcester, MA 01605, USA.
Abstract
Enforced expression of the HoxB4 gene promotes expansion of hematopoietic stem cells (HSCs) and enhances hematopoietic development of both murine and human embryonic stem (ES) cells. HoxB4- expanded HSCs have also been shown to retain their normal potential for differentiation and longterm self-renewal in vivo without the development of leukemia, suggesting that manipulation of HoxB4 expression might represent an effective way to expand functional HSCs for use in transplantation medicine. However, the genetic modification of cells poses clinical concerns, including a potentially increased risk of tumor genicity. Constitutive high-level ectopic viral expression of HoxB4 can also produce perturbations in the lineage differentiation of HSCs, an indication that uncontrolled HoxB4 manipulation may not be a satisfactory therapeutic strategy. Here we demonstrate that recombinant HoxB4 protein fused with a triple protein transduction domain (tPTD) promotes hematopoietic development of hES cells. The tPTD-HoxB4 protein enhanced the development of erythroid, myeloid, and multipotential progenitors in both early- and late-stage embryoid bodies (EBs). This effect varied considerably between different hES cell lines. Addition of the tPTD-HoxB4 protein did not alter the globin gene expression pattern; progeny derived from hES cells expressed high levels of embryonic (epsilon) and fetal (gamma) globin genes with or without tPTD-HoxB4 treatment. CD34+ cells derived from hES cells engrafted in bone marrow when transplanted into fetal CD1 mice, although supplementation of the differentiation medium with tPTD-HoxB4 protein did not result in increased repopulating capacity. This suggests that other gene(s), together with HoxB4, are required for generating more competitive HSCs. In summary, our study demonstrates that the tPTD-HoxB4 protein can be used with other recombinant proteins to efficiently generate transplantable HSCs from human ES cells.
Interview with Dr Shi-Jiang Lu senior director at Stem Cell and Regenerative International, Inc and scientific advisor at Advanced Cell Technology Inc
5-25-2010 by a representative of Proteintech Group
Dr Lu is a senior director at Stem Cell and Regenerative International Inc., and scientific advisor at Advanced Cell Technology Inc., MA, US. He is also adjunct professor at Cha University, Seoul, South Korea. With over 50 scientific publications to his name, Shi-Jiang has authored many key papers in stem cell research, many in collaboration with Dr Robert Lanza. Dr Lu completed his PhD at the University of Toronto, Canada. Here he tells us about his current research interests.
Tell us about the research you are working on at the moment.
My current work focuses on human ES and iPS cell research; specifically human ES and iPS cell differentiation toward specific lineages for clinical applications. Several research directions are currently ongoing in my group:
Donor-less Blood: The shortage of available blood is a constant and critical problem necessitating continual blood drives by agencies such as the Red Cross. We have demonstrated in our scientific paper (Nature Methods, 4:501-509, 2007) that hemangioblasts, a precursor to multiple cell types, can be produced from human embryonic stem cells on a large scale under serum-free conditions. Further, we have been able to show that these hemangioblasts can give rise to both hematopoietic and vascular cell lineages. Importantly, they can be used to create large quantities of erythrocytes (red blood cells), which carry oxygen to tissues throughout the body (Blood, 112:4475-4484, 2008). With our patent-protected technology we are working to produce a donor-less universal blood supply in limitless quantity to treat patients with rare blood types or in emergency situations such as for traumas or on the battlefield.
Donor-less Blood Platelets: Blood platelets are important for clotting and are used to treat a variety of illnesses requiring constant transfusions. Despite this critical need, there is a shortage of available platelets. With our hemangioblast technology we have developed a novel system to efficiently generate megakaryocytes from human embryonic stem cells. Megakaryocytes are bone marrow cells that are responsible for the production of platelets. Other researchers have been able to produce platelets but only by using serum or stromal cells which are animal-derived products. Our megakaryocyte technology produces a safe, reliable source of blood platelets free of animal products.
Dr Shi-Jiang Lu
Donor-less Bone Marrow: Bone marrow is used to treat diseases such as leukemia as well as for cancer patients requiring bone marrow replacement. With our hemangioblast technology we are working to see if transplanted hemangioblasts that we have derived from embryonic stem cells have the capability to grow in a recipient’s bone marrow and produce new bone marrow. Since these cells can be derived in large quantities under serum-free and reproducible conditions, the use of these cells would not be limited by availability, but rather the cells could be grown and differentiated for the precise clinical requirement of the individual with the potential for multiple infusions over the lifetime of the patient if required. For hemangioblasts from human embryonic stem cells, the ability to create banks of cell lines with matched or reduced incompatibility could potentially reduce or eliminate the need for immunosuppressive drugs and/or immunomodulatory protocols altogether. Inasmuch as induced pluripotent stem cell-derived hemangioblasts could be produced from a patient’s own cells, tissue incompatibility could be eliminated completely to avoid a major source of transplantation-related complications.
Retinal Vascular Therapies: Three major eye diseases associated with abnormalities in retinal vasculature (blood circulation in the eye) are glaucoma, diabetic retinopathy, and retinal vein occlusions. All three of these devastating diseases are leading causes of blindness. Glaucoma alone affects over three million people in the United States and about 40% of Americans diagnosed with diabetes have some stage of diabetic retinopathy. We have shown that when hemangioblasts, derived from human embryonic stem cells are injected into the eyes of mice they are capable of repairing damaged retinas and partially restoring vision (Nature Methods, 4:501-509, 2007 and Regenerative Medicine, 4:37-47, 2009). We are working to produce hemangioblasts on a large scale, differentiate them into the cells necessary for eye treatment, and begin a clinical trial to test the efficacy of these cells for the treatment of eye diseases.
Cardiovascular Therapies: Each year, about 1.1 million people in the United States have heart attacks and almost half of them die. We have shown that injection of hemangioblasts, which we have derived from human embryonic stem cells, into mice experiencing induced heart attacks has reduced the mortality rate by 50%. While the mechanism of this success is unknown we suspect it is due to the ability of these hemangioblasts to restore blood flow to areas damaged by heart attack. We are working to study its effectiveness in rats, a more complex model than mice, and thus more similar to humans. The therapeutic potential of this treatment is enormously promising.
Ischemic Vascular Therapies: Ischemia is a condition in which blood flow (and thus oxygen) is restricted to a part of the body. In its most severe form it can cause death. Patients suffering from diabetes can experience ischemia of the limbs requiring amputation. Our studies have demonstrated that injecting hemangioblasts into the ischemic hind limbs of mice has restored the blood flow in those areas to near normal levels. In other studies we have shown that introducing the hemangioblasts into mice wounds results in significantly enhanced healing. We are working to study the effectiveness of this treatment in rats in order to test whether hemangioblasts will be suitable for treatment of ischemia and wounds caused by a number of diseases, such as diabetes.
What was your experience of the OCT4, SOX2, NANOG and LIN28 antibodies and of Proteintech in general?
I tested the four antibodies, all of them are excellent. Most antibodies from Proteintech are excellent and your service is also outstanding. I always recommend my colleagues to Proteintech.
Why did you pursue a career in scientific research?
When I was a college student, to be a scientist was my dream. There was no other career at that time that attracted me the most.
Name one high and one low of your career so far.
Low: Grant reviewer’s comments that “Human ES cell lines are available, why are you using monkey ES cells for this research”: The fact is that the US government has not approved the use of federal funding for human ES cell research. When I resubmitted the proposal including human ES cell lines, the reviewers came back: “You have used monkey ES cells in your research for several years, why do you want to switch to human ES cells”.
High: Half a year after joining Advanced Cell Technology, I discovered and identified hemangioblasts derived from human ES cells.
If you could give just one piece of advice to a young PhD student, what would it be?
Be patient and concentrate on the research you are interested in. Award will come sooner or later.
What do you think will be the most important development in your field in the next decade?
The establishment of safe and authentic human iPS cell lines that are comparable, if not identical, to human ES cell lines. The differentiated derivatives from these safe iPS cells will be used in clinical settings.
What’s your favorite Proteintech antibody?
Anti-human CD31 (PECAM1) antigen antibody.
Who’s your most respected scientist?
Dr Fred Sanger who developed both protein and DNA sequencing.
Western blot or immunofluorescence?
I’ve done a lot of immunofluorescence stains on cells and tissues, sometimes you have to be aware of false positive signals. As for WB, you need a lot of material to start. You also can not tell the location of the protein in a specific cell.
PC or Mac?
I always use PC, no Mac experience.
Monoclonal or polyclonal?
No preference, what I care the most is the specificity.
Science or Nature?
No preference, both are excellent journals.
Stem Cell Research: Science, Not Politics
http://www.huffingtonpost.com/susan-l-solomon/stem-cell-research-scienc_b_734769.html
DOJ: Congress never meant to ban embryonic stem cell research
September 21, 2010
http://www.massdevice.com/news/doj-congress-never-meant-ban-embryonic-stem-cell-research
Yes, and not all, of course, but a great part of the freeze has been due to the political atmosphere which has been restrictive in many ways including in its impact on funding for ACTC.
I think this was posted sometime in the past so it's just a reminder from May 2009 as well as the latest indication I can find of blood cell work at Stem Cell and Regenerative Medicine International:
Generation of Human Induced Pluripotent Stem Cells by Direct Delivery of Reprogramming Proteins
http://www.cell.com/cell-stem-cell/fulltext/S1934-5909(09)00214-8
Cha is our partner in the blood cell program and has a majority interest in it:
Leading Korean Biotech Company & Advanced Cell Technology Form JV
December 1, 2008
http://www.advancedcell.com/news-and-media/press-releases/leading-korean-biotech-company-and-advanced-cell-technology-form-jv/
The JV, located at ACTC facilities was initially named Allied Cell Technology but was quickly renamed:
Joint Venture Between CHA Biotech and Advanced Cell Technology to be called Stem Cell & Regenerative Medicine International
December 30, 2008
http://www.advancedcell.com/news-and-media/press-releases/joint-venture-between-cha-biotech-and-advanced-cell-technology-to-be-called-stem-cell-and-regenerativ/
Univ of Calif seeks to intervene in stem cell suit
The Associated Press
Posted: 09/20/2010 05:32:05 PM PDT
OAKLAND, Calif.—The University of California wants to formally intervene on behalf of stem cell scientists in a lawsuit seeking to deny federal funding for the controversial research.
The university said in a statement Monday that it wants a role in the litigation because of the suit's potential impact on institutions pursuing "lifesaving research" into human embryonic stem cells.
The university says scientists are conducting stem cell research on all 10 of its campuses.
U.S. District Court Judge Royce Lamberth in August blocked human embryonic stem cell research from receiving federal funds after concluding that opponents would likely succeed in a lawsuit challenging President Obama's stem cell policy.
A federal appeals court earlier this month temporarily stayed Lamberth's order while the case moves forward.
US government argues for stem cell stay
The legal battle over federal funding for human embryonic stem cell research in the US continues: in yet another court filing today (PDF here), government lawyers reiterated their arguments for why an appeals court should lift a ban on such funding imposed by a district court judge last month. ........
http://blogs.nature.com/news/thegreatbeyond/2010/09/us_government_argues_for_stem.html
Stem-cell research pushed to top of Congress' agenda
http://www.denverpost.com/politics/ci_16077163
Justice Department Seeks Stay Of Stem-Cell Ruling
http://online.wsj.com/article/BT-CO-20100831-711014.html
First tests for stem cell therapy are near
http://www.washingtonpost.com/wp-dyn/content/article/2010/08/29/AR2010082901854.html
Plaintiffs in stem cell lawsuit made news for other issues
James Sherley once staged a hunger strike to protest a denial of tenure, which he blamed on racism. Theresa Deisher claimed harassment by former colleagues amid an SEC inquiry.
http://www.latimes.com/news/science/la-sci-stem-cells-plaintiffs-20100825,0,7279207.story
CIRM Director Prieto Says hESC Research Ruling 'Almost Beyond Belief'
California Stem Cell Report
CIRM Director Francisco Prieto, a Sacramento physician, sent in the following comment on our item on today's ruling temporarily halting federal funding of hESC research.
"I think you're opening hits the nail on the head: this decision 'makes clear the importance of alternative funding sources such as the California stem cell agency.' It is almost beyond belief that the court could find that the plaintiffs really met the high standards for a preliminary injunction to call an immediate halt to Federal runding, i.e. that 'there is a substantial likelihood of success on the merits; (2) that the plaintiff would suffer irreparable injury absent an injunction; (3) that an injunction would not substantially injure other interested parties.' I believe none of these are true. Certainly researchers using adult stem cells have had unfettered access to compete for NIH funding since the Bush decision in 2001, and continue to be able to compete for funding. It seems almost obvious that this decision if upheld would injure substantially other interested parties - all the millions of people with chronic disease who hope that this research may lead someday to a cure."
Ruling a Blow to Stem Cell Research, LA Times
http://www.latimes.com/news/nationworld/...
.....Scientists working with embryonic stem cells said patients will suffer by having to wait longer for science to develop new treatments and cures.
Advanced Cell Technology Inc. is using the cells to grow retinal pigment epithelium cells that restored vision in rats and mice with a rare childhood disease called Stargardt's macular dystrophy. The Santa Monica-based company has asked the Food and Drug Administration for permission to use the cells in a clinical trial. But without any prospect of federal funding, the research would be in doubt, said Dr. Robert Lanza, the company's chief scientific officer.
"This is criminal," Lanza said. "We are talking about people going blind, people who are dying from a terrifying array of diseases."
Even in California, where Proposition 71 made billions of dollars available for research involving human embryonic stem cells, scientists face a chaotic future because so many rely on NIH grants, said Alan Trounson, president of the California Institute of Regenerative Medicine. .......
Reportedly the Justice Department has Lamberth's decison under review. Does anyone know what that process would entail and how long it might take?
Disturbing confusion on meaning of Judge's decision:
U.S. Court Rules Against Obama’s Stem Cell Policy
http://www.nytimes.com/2010/08/24/health/policy/24stem.html
.....The ruling came as a shock to scientists at the National Institutes of Health and at universities across the country, which had viewed the Obama Administration’s new policy and the grants provided under it as settled law. Scientists scrambled Monday evening to assess the ruling’s immediate impact on their work.
“I have had to tell everyone in my lab that when they feed their cells tomorrow morning, they better use media that has not been funded by the federal government,” said Dr. George Q. Daley, director of the stem cell transplantation program at Children’s Hospital Boston, referring to food given cells. “This ruling means an immediate disruption of dozens of labs doing this work since the Obama Administration made its order.”
In his ruling, Chief Judge Royce C. Lamberth of the U.S. District Court for the District of Columbia wrote that his temporary injunction returns federal policy to the “status quo,” but few officials, scientists or lawyers in the case were sure Monday night what that meant. Dr. Daley was among those who said they believed that it meant that work funded under the new rules had to stop immediately; others said that it meant that the health institutes had to use Bush Administration rules to fund future grants. .........
Recent job ad:
Monday, 28th June 2010 Positions – Stem Cell & Regenerative Medicine International
Senior and Junior Level Scientist Positions in Stem Cell Research
Stem Cell & Regenerative Medicine International (“Stem International”) is seeking innovative and motivated senior level scientists to join its world-renowned research team in Marlborough, Massachusetts. As a newly formed joint venture between Advanced Cell Technology and CHA Biotech of Korea, Stem International is a powerful partnership of scientific expertise and capabilities focused on achieving the first clinical application of stem cell therapies. Led by pioneers in the stem cell field, we offer a dynamic and challenging work environment in a state-of-the-art research facility.
Senior and Junior Level Scientists
We are seeking two (2) full time Senior and Junior Level Scientists in stem cell and hematopoietic cell biology. Successful candidates will have PhD or MD, PhD/MD degree with hematopoietic cell or human ES/iPS cell research background of at least 1-3+ years of experience in an academic or R&D environment. Experience in human ES/iPS cells of in vitro differentiation, especially mesoderm progenitor differentiation a plus. One position is responsible for investigating the generation, maturation and enucleation of red blood cells derived from hES/iPS cells (see Lu et al: Generation of functional hemangioblasts from human embryonic stem cells. Nature Methods, 4: 501-509, 2007; Lu et al: Biologic properties and enucleation of red blood cells from human embryonic stem cells. Blood, 112:4475-4484, 2008; Feng et al: Hemangioblastic derivatives from human induced pluripotent stem cells exhibit limited expansion and early senescence. Stem Cells, 28:704-712, 2010). Another position is responsible for the generation of functional megakaryocytes/platelets from human ES/iPS cells (see Li et al: Large scale generation of functional megakaryocytes from human embryonic stem cells (hESCs) under stromal-free conditions. Blood, 114: Abs. 2540, 2009). The candidate must be creative, independent, highly organized, reliable, with demonstrated ability to initiate and carry out projects, trouble shoot, and quickly learn new skills.
To Apply:
Please, send or email resume with detailed description of research background and technical skills that meet the requirements, and a list of publications to:
Shi-Jiang Lu, PhD
Senior Director
Stem Cell & Regenerative Medicine International
33 Locke Drive, Marlborough, MA 01752
Good work here, rocky. I do think ACTC is, among other things, making the case that they will be a major player not only in the hESC realm with which they are most identified but also in the iPS realm where they may feel they have been misunderestimated, so to speak.
"Hi Rocky, how does that change if I close my eyes and cover my ears and sing loudly?"
I'm not sure about that, rumit, but if you stick your head in the ground you get a disease called OStreching.
If ACTC gets the nod relatively soon it seems very likely that they will be able to recruit patients and complete trials much faster than GERN.
Yes, interstate, it makes my eyes water. :)
Good idea fuller. AIG will certainly cover us.
Great info louisa and rocky.
I am surprised by Caldwell. He should be aware of the possibility that, unless he really believes he is going to bring the rest of us along with him, he is placing himself in a biocentric moral hazard (that is not to say that doing so in this Market world is especially unique).
rocky, maybe Caldwell is angling to replace Blankfein.